Personalizing breast cancer therapy: biomarker test may improve response
NCT ID NCT06441890
First seen Aug 21, 2026 · Last updated Aug 21, 2026
Summary
This phase 2 trial is testing whether using a biomarker test (MammaPrint/BluePrint) to guide treatment choices can improve outcomes for people with early-stage HER2-positive breast cancer. Participants receive standard chemotherapy (paclitaxel, nab-paclitaxel, or docetaxel) combined with targeted therapies (trastuzumab and pertuzumab) before surgery. The main goal is to see if this approach leads to a higher rate of complete tumor disappearance at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of chemotherapy drugs (paclitaxel, nab-paclitaxel, or docetaxel) with targeted antibodies (trastuzumab and pertuzumab), chosen based on a tumor biomarker test.
- What this could lead to
- If successful, this approach could personalize breast cancer treatment, increasing the chance of a complete response and potentially improving long-term outcomes.
- What could go wrong
- This is a small phase 2 trial, so results may not be conclusive. The biomarker-guided approach may not improve response rates, and chemotherapy side effects remain a risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new tracers make many cancers light up on scans?
- Can talk therapy for sleep beat cancer fatigue?
- A card game could open the door to better End-of-Life conversations
- Essential oils vs. chemo nerve pain: a natural remedy put to the test
- Could a 48-Hour fast tame Chemotherapy's worst side effects?
- Can we predict the painful cords that follow breast cancer surgery?